Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EOLS Evolus	$6.51 +1.7%	$9.03	$5.71 ▼ $17.82	$413.99M	1.12	2.18 million shs	1.64 million shs
GLSI Greenwich LifeSciences	$11.78 -4.6%	$10.45	$8.06 ▼ $16.50	$165.10M	1.65	73,525 shs	51,584 shs
PHAT Phathom Pharmaceuticals	$10.46 +0.8%	$9.15	$2.21 ▼ $19.71	$736.40M	0.45	1.11 million shs	1.18 million shs
REPL Replimune Group	$5.10 -3.0%	$8.42	$2.68 ▼ $17.00	$409.79M	0.67	24.28 million shs	3.29 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EOLS Evolus	+10.92%	-28.17%	-32.49%	-35.94%	-50.96%
GLSI Greenwich LifeSciences	-1.12%	+5.38%	+13.93%	+31.10%	-7.70%
PHAT Phathom Pharmaceuticals	+0.97%	+23.87%	+13.07%	+219.38%	-13.72%
REPL Replimune Group	+5.21%	-16.93%	-52.14%	-25.11%	-45.03%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EOLS Evolus	3.5536 of 5 stars	3.4	0.0	3.5	1.0	3.3	0.6
GLSI Greenwich LifeSciences	1.6276 of 5 stars	3.5	1.0	0.0	2.0	1.7	0.0
PHAT Phathom Pharmaceuticals	3.3143 of 5 stars	3.5	2.0	0.0	2.3	5.0	0.6
REPL Replimune Group	4.6959 of 5 stars	4.2	4.0	4.5	2.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EOLS Evolus	2.80	Moderate Buy	$21.25	226.42% Upside
GLSI Greenwich LifeSciences	3.00	Buy	$39.00	231.07% Upside
PHAT Phathom Pharmaceuticals	3.00	Buy	$17.50	67.24% Upside
REPL Replimune Group	2.33	Hold	$7.67	50.47% Upside

Current Analyst Ratings Breakdown

Latest GLSI, REPL, EOLS, and PHAT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2025	EOLS Evolus	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$21.00 ➝ $18.00
8/6/2025	EOLS Evolus	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$27.00 ➝ $20.00
8/6/2025	EOLS Evolus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$22.00
7/30/2025	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
7/23/2025	REPL Replimune Group	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$17.00 ➝ $3.00
7/23/2025	REPL Replimune Group	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Underperform	$27.00 ➝ $2.00
7/23/2025	REPL Replimune Group	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/22/2025	REPL Replimune Group	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/22/2025	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/22/2025	REPL Replimune Group	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$31.00 ➝ $6.00
7/22/2025	REPL Replimune Group	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$21.00 ➝ $3.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EOLS Evolus	$266.27M	1.58	N/A	N/A	($0.29) per share	-22.45
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	$0.19 per share	N/A
PHAT Phathom Pharmaceuticals	$55.25M	13.44	N/A	N/A	($5.72) per share	-1.83
REPL Replimune Group	N/A	N/A	N/A	N/A	$4.31 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EOLS Evolus	-$50.42M	-$0.98	N/A	N/A	N/A	-22.31%	-759.04%	-24.63%	N/A
GLSI Greenwich LifeSciences	-$15.79M	-$1.26	N/A	N/A	N/A	N/A	-450.87%	-333.18%	8/13/2025 (Estimated)
PHAT Phathom Pharmaceuticals	-$334.33M	-$4.73	N/A	N/A	N/A	-289.51%	N/A	-90.40%	N/A
REPL Replimune Group	-$247.30M	-$3.24	N/A	N/A	N/A	N/A	-69.34%	-52.81%	8/14/2025 (Estimated)

Latest GLSI, REPL, EOLS, and PHAT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	N/A	GLSI Greenwich LifeSciences	-$0.24	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q1 2026	REPL Replimune Group	-$0.83	-$0.95	-$0.12	-$0.95	$0.50 million	N/A
5/22/2025	Q4 2025	REPL Replimune Group	-$0.75	-$0.82	-$0.07	-$0.82	N/A	N/A
5/20/2025	Q1 2025	GLSI Greenwich LifeSciences	-$0.24	-$0.25	-$0.01	-$0.25	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EOLS Evolus	N/A	N/A	N/A	N/A	N/A
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EOLS Evolus	22.00	2.27	1.86
GLSI Greenwich LifeSciences	N/A	1.91	1.91
PHAT Phathom Pharmaceuticals	N/A	2.38	2.35
REPL Replimune Group	0.21	6.94	7.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EOLS Evolus	90.69%
GLSI Greenwich LifeSciences	4.16%
PHAT Phathom Pharmaceuticals	99.01%
REPL Replimune Group	92.53%

Insider Ownership

Company	Insider Ownership
EOLS Evolus	5.90%
GLSI Greenwich LifeSciences	51.67%
PHAT Phathom Pharmaceuticals	23.00%
REPL Replimune Group	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EOLS Evolus	170	64.68 million	60.87 million	Optionable
GLSI Greenwich LifeSciences	3	13.37 million	6.46 million	Not Optionable
PHAT Phathom Pharmaceuticals	110	70.94 million	54.63 million	Optionable
REPL Replimune Group	210	78.06 million	74.00 million	Optionable

GLSI, REPL, EOLS, and PHAT Headlines

Recent News About These Companies

ROSEN, LEADING INVESTOR COUNSEL, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – REPL

August 13 at 4:45 PM | globenewswire.com

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in Replimune Group, Inc. Lawsuit – REPL

August 13 at 4:39 PM | globenewswire.com

NASDAQ: REPL: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Class Action Lawsuit Against Replimune Group, Inc.

August 13 at 4:25 PM | businesswire.com

Shareholders who lost money on Replimune Group, Inc. (NASDAQ: REPL) Should Contact Wolf Haldenstein Immediately as Lead Plaintiff Deadline is September 22nd

August 13 at 3:26 PM | globenewswire.com

INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Replimune Group (REPL) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm

August 13 at 1:40 PM | globenewswire.com

Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma Drug - Hagens Berman

August 13 at 12:13 PM | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL

August 13 at 10:37 AM | globenewswire.com

Jefferies Keeps Their Buy Rating on Replimune Group (REPL)

August 13 at 3:47 AM | theglobeandmail.com

REPL Stock News: Investors with Large Losses Should Contact Robbins LLP for Information About Leading the Replimune Group, Inc. Class Action Lawsuit

August 12 at 7:02 PM | prnewswire.com

FDA Review Changes and the Impact on Trial Design

August 12 at 5:33 PM | appliedclinicaltrialsonline.comA

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

August 12 at 11:01 AM | globenewswire.com

Replimune Group, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - REPL

August 12 at 9:00 AM | prnewswire.com

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Replimune ...

August 11 at 7:42 PM | reflector.comR

Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma Drug - Hagens Berman

August 11 at 5:14 PM | globenewswire.com

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Replimune Group, Inc. (REPL) Shareholders

August 11 at 4:27 PM | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL

August 11 at 10:00 AM | prnewswire.com

Class Action Filed Against Replimune Group, Inc. (REPL) - September 22, 2025 Deadline to Join - Contact The Gross Law Firm

August 11 at 8:45 AM | prnewswire.com

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Replimune Group, Inc. (NASDAQ: REPL)

August 11 at 8:30 AM | globenewswire.com

Shareholders who lost money on Replimune Group, Inc. (NASDAQ: REPL) Should Contact Wolf Haldenstein Immediately as Lead Plaintiff Deadline is September 22nd

August 11 at 8:04 AM | prnewswire.com

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Replimune Group, Inc. ...

August 10 at 9:13 AM | gurufocus.com

Replimune Group (REPL) Expected to Announce Earnings on Thursday

August 7, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLSI, REPL, EOLS, and PHAT Company Descriptions

Evolus NASDAQ:EOLS

$6.51 +0.11 (+1.72%)

Closing price 04:00 PM Eastern

Extended Trading

$6.63 +0.12 (+1.84%)

As of 06:42 PM Eastern

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Greenwich LifeSciences NASDAQ:GLSI

$11.78 -0.57 (-4.62%)

Closing price 04:00 PM Eastern

Extended Trading

$11.80 +0.03 (+0.21%)

As of 06:44 PM Eastern

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Phathom Pharmaceuticals NASDAQ:PHAT

$10.46 +0.08 (+0.81%)

Closing price 03:59 PM Eastern

Extended Trading

$10.51 +0.05 (+0.44%)

As of 07:53 PM Eastern

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Replimune Group NASDAQ:REPL

$5.10 -0.16 (-2.95%)

Closing price 03:59 PM Eastern

Extended Trading

$5.24 +0.15 (+2.94%)

As of 07:56 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time